Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: Impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease

Journal of Cardiology

Volumn 59, Issue 1, 2012, Pages 50-56

  Uemura, Yusuke ^a,b   Watarai, Masato ^a   Ishii, Hideki ^b   Koyasu, Masayoshi ^a,b   Takemoto, Kenji ^a   Yoshikawa, Daiji ^b   Shibata, Rei ^b   Matsubara, Tatsuaki ^c   Murohara, Toyoaki ^b  

^a ANJO KOSEI HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Cholesterol screening; Cholesterol lowering drugs; Clinical trials; Drug therapy

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; DRUG DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; MALONDIALDEHYDE LOW DENSITY LIPOPROTEIN, HUMAN; MALONDIALDEHYDE-LOW DENSITY LIPOPROTEIN, HUMAN; PYRROLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; JAPANESE; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GLUCOSE INTOLERANCE; OXIDATION REDUCTION REACTION;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY DISEASE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE INTOLERANCE; HEPTANOIC ACIDS; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; OXIDATION-REDUCTION; PROSPECTIVE STUDIES; PYRROLES;

EID: 84855195518     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.09.001     Document Type: Article

References (35)

1. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., Holman R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823-828.
2. Kinlay S., Timms T., Clark M., Karam C., Bilodeau T., Ridker P.M., Rifai N., Carlson W., Lloyd-Jones D.M., Johnstone M., Rubenstein J., Alexander S., Orav J., Stone P.H. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002, 89:1205-1207. Vascular Basis Study Group.
3. Ishii H., Nishio M., Takahashi H., Aoyama T., Tanaka M., Toriyama T., Tamaki T., Yoshikawa D., Hayashi M., Amano T., Matsubara T., Murohara T. Comparison of atorvastatin 5 and 20mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin Ther 2010, 32:2337-2347.
4. Nissen S.E. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004, 292:1365-1367.
5. Kosoglou T., Statkevich P., Johnson-Levonas A.O., Paolini J.F., Bergman A.J., Alton K.B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005, 44:467-494.
6. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., Veltri E.P. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 40:2125-2134.
7. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., Visseren F.L., Sijbrands E.J., Trip M.D., Stein E.A., Gaudet D., Duivenvoorden R., Veltri E.P., Marais A.D., de Groot E., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
8. Bulut D., Hanefeld C., Bulut-Streich N., Graf C., Mügge A., Spiecker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome-effect of different lipid-lowering regimens. Cardiology 2005, 104:176-180.
9. Olijhoek J.K., Hajer G.R., van der Graaf Y., Dallinga-Thie G.M., Visseren F.L. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol 2008, 52:145-150.
10. Tamura A., Wanatabe T., Nasu M. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circ J 2003, 67:816-820.
11. Ueda S., Miyake I., Takata K., Shimizu N., Shirotani K., Ishida S., Yonetitsu K., Maeyama T., Saito F., Saito H., Yamagishi S. Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia. Int J Cardiol 2010, 146:420-421.
12. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
13. Bonora E., Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia 2001, 44:2107-2114.
14. Lally S., Tan C.Y., Owens D., Tomkin G.H. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006, 49:1008-1016.
15. Ceriello A., Taboga C., Tonutti L., Giacomello R., Stel L., Motz E., Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996, 39:469-473.
16. Kawano H., Motoyama T., Hirashima O., Hirai N., Miyao Y., Sakamoto T., Kugiyama K., Ogawa H., Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34:146-154.
17. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98:1487-1494.
18. Tani S., Watanabe I., Anazawa T., Kawamata H., Tachibana E., Furukawa K., Sato Y., Nagao K., Kanmatsuse K., Kushiro T. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol 2005, 96:1089-1094. Surugadai Atherosclerosis Regression Investigators.
19. Tani S., Dimayuga P.C., Anazawa T., Chyu K.Y., Li H., Shah P.K., Cercek B. Aberrant antibody responses to oxidized LDL and increased intimal thickening in apoE-/- mice exposed to cigarette smoke. Atherosclerosis 2004, 175:7-14.
20. Azar R.R., Badaoui G., Sarkis A., Azar M., Aydanian H., Harb S., Achkouty G., Kassab R. Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. Am J Cardiol 2010, 106:193-197.
21. Brewer H.B., Rader D.J. HDL: structure, function and metabolism. Prog Lipid Res 1991, 30:139-144.
22. Rader D.J., Hoeg J.M., Brewer H.B. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994, 120:1012-1025.
23. Biswass S., Ghoshal P.K., Mandel S.C., Mandal N. Association of low-density lipoprotein particle size and ratio of different lipoproteins and apolipoproteins with coronary heart disease. J Cardiol 2008, 52:118-126.
24. Kugiyama K., Doi H., Takazoe K., Kawano H., Soejima H., Mizuno Y., Tsunoda R., Sakamoto T., Nakano T., Nakajima K., Ogawa H., Sugiyama S., Yoshimura M., Yasue H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999, 99:2858-2860.
25. Nakamura T., Takano H., Umetani K., Kawabata K., Obata J.E., Kitta Y., Kodama Y., Mende A., Ichigi Y., Fujioka D., Saito Y., Kugiyama K. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005, 181:321-327.
26. Hiki M., Shimada K., Kume A., Sumiyoshi K., Fukao K., Inoue N., Mokuno H., Miyazaki T., Daida H. Serum level of remnant cholesterol and oxidized low-density lipoprotein in patients with coronary artery disease. J Cardiol 2009, 53:108-116.
27. Miettinen T.A., Gylling H., Lindbohm N., Miettinen T.E., Rajaratnam R.A., Relas H. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141:131-137. Finnish Treat-to-Target Study Investigators.
28. Matthan N.R., Pencina M., LaRocque J.M., Jacques P.F., D'Agostino R.B., Schaefer E.J., Lichtenstein A.H. Alternations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD. J Lipid Res 2009, 50:1927-1935.
29. Gylling H., Miettinen T.A. Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis 1996, 126:325-332.
30. O'Keefe J.H., Bell D.S. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007, 100:899-904.
31. Raffel O.C., Tearney G.J., Gauthier D.D., Halpern E.F., Bouma B.E., Jang I.K. Relationship between a systemic inflammatory marker, plaque inflammation, and plaque characteristics determined by intravascular optical coherence tomography. Arterioscler Thromb Vasc Biol 2007, 27:1820-1827.
32. Ishii H., Toriyama T., Aoyama T., Takahashi H., Amano T., Hayashi M., Tanaka M., Kawamura Y., Yasuda Y., Yuzawa Y., Maruyama S., Matsuo S., Matsubara T., Murohara T. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis. Circ Cardiovasc Intervent 2009, 2:513-518.
33. Rossebø A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., Gerdts E., Gohlke-Bärwolf C., Holme I., Kesäniemi Y.A., Malbecq W., Nienaber C.A., Ray S., Skjaerpe T., Wachtell K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
34. Standberg T.E., Tilvis R.S., Pitkala K.H., Miettinen T.A. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol 2006, 48:708-714.
35. Miettinen T.A., Gylling H., Strandberg T., Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998, 316:1127-1130.